CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $5.16M, lower than 95% of all stocks globally
- PositionGross margin is 100%, higher than 95% of its Biotechnology peers (median 67.1%)
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
5.61BCNY834.22M · vs all stocks (USD)
Revenue (TTM)
34.67MCNY5.16M · vs all stocks (USD)
Profit Margin
-268.76%vs Biotechnology peers
Beta
0.6690xvs all stocks
52-Week Change
-25.96%vs all stocks
Market Capitalization
5.61BCNY834.22M · vs all stocks (USD)
Enterprise Value
5.16BCNY766.65M · vs all stocks (USD)
Price to Book (MRQ)
8.71xvs Biotechnology peers
Enterprise to Revenue
148.71xvs Biotechnology peers
Enterprise to EBITDA
-30.85xvs Biotechnology peers
Gross Margin
100.00%vs Biotechnology peers
Profit Margin
-268.76%vs Biotechnology peers
Operating Margin
-63.80%vs Biotechnology peers
Return on Assets (TTM)
-12.94%vs Biotechnology peers
Return on Equity (TTM)
-13.09%vs Biotechnology peers
Revenue (TTM)
34.67MCNY5.16M · vs all stocks (USD)
Revenue per Share (TTM)
0.3130CNYUpdated Aug 21, 2026Quarterly Revenue Growth
1300.00%vs Biotechnology peers
Gross Profit (TTM)
34.40MCNY5.12M · vs all stocks (USD)
EBITDA (TTM)
-167.11MCNY-24.85M · vs all stocks (USD)
Net Income (TTM)
-93.17MCNY-13.86M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
19614.84%vs Biotechnology peers
Operating Cash Flow (TTM)
-115.36MCNY-17.16M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-117.45MCNY-17.47M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00CNYUpdated Aug 21, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
8.67MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
266.10KCNYFY2025 · Dec 31, 2025Gross Profit
8.40MCNYFY2025 · Dec 31, 2025Operating Income
-146.43MCNY-21.78M · vs all stocks (USD)
Pre-tax Income
-128.83MCNYFY2025 · Dec 31, 2025Net Income
-128.83MCNYFY2025 · Dec 31, 2025EBIT
-128.70MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
-128.65MCNYFY2025 · Dec 31, 2025Research & Development
196.70MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
6.35MCNYFY2025 · Dec 31, 2025Other Operating Expenses
46.42KCNYFY2025 · Dec 31, 2025Non-operating Interest Income
664.19KCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
133.13KCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.8700CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.8700CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
148.09MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
148.09MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-128.83MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-141.41MCNYFY2025 · Dec 31, 2025Free Cash Flow
-144.61MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
17.59MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-128.83MCNYFY2025 · Dec 31, 2025Other Non-cash Items
778.59KCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-13.68MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
329.63KCNYFY2025 · Dec 31, 2025Capital Expenditures
-3.20MCNYFY2025 · Dec 31, 2025Purchase of Investments
-3.01BCNYFY2025 · Dec 31, 2025Sale of Investments
3.18BCNYFY2025 · Dec 31, 2025Other Investing Activity
-15.94MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
157.48MCNYFY2025 · Dec 31, 2025Other Financing Charges
-4.79MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-4.79MCNYFY2025 · Dec 31, 2025Shares Outstanding
148.72MSharesUpdated Aug 21, 2026Float Shares
54.40MSharesUpdated Aug 21, 2026% Held by Insiders
72.31%vs all stocks
% Held by Institutions
6.86%vs all stocks
Total Cash (MRQ)
651.40MCNY96.87M · vs all stocks (USD)
Total Cash per Share (MRQ)
4.38CNYUpdated Aug 21, 2026Total Debt (MRQ)
12.62MCNY1.88M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0190xvs Biotechnology peers
Current Ratio (MRQ)
6.89xvs Biotechnology peers
Book Value per Share (MRQ)
4.47CNYUpdated Aug 21, 2026Total Assets
791.23MCNY117.66M · vs all stocks (USD)
Total Current Assets
704.84MCNYFY2025 · Dec 31, 2025Total Liabilities
111.05MCNYFY2025 · Dec 31, 2025Total Non-current Assets
86.39MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
8.92MCNYFY2025 · Dec 31, 2025Total Current Liabilities
102.14MCNYFY2025 · Dec 31, 2025Cash
17.59MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
17.59MCNYFY2025 · Dec 31, 2025Other Short-term Investments
654.26MCNYFY2025 · Dec 31, 2025Accounts Receivable
331.67KCNYFY2025 · Dec 31, 2025Inventory
3.08MCNYFY2025 · Dec 31, 2025Accounts Payable
88.53MCNYFY2025 · Dec 31, 2025Short-term Debt
4.77MCNYFY2025 · Dec 31, 2025Long-term Debt
8.86MCNYFY2025 · Dec 31, 2025Common Stock (Book)
148.72MCNYFY2025 · Dec 31, 2025Retained Earnings
-1.15BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
680.18MCNY101.15M · vs all stocks (USD)
52-Week Low
29.71CNYUpdated Aug 21, 202652-Week High
53.55CNYUpdated Aug 21, 202652-Week Change
-25.96%vs all stocks
Beta
0.6690xvs all stocks
50-Day MA
35.57CNYUpdated Aug 21, 2026200-Day MA
37.86CNYUpdated Aug 21, 2026Avg 10-Day Volume
2.97MSharesUpdated Aug 21, 2026Avg 30-Day Volume
3.37MSharesUpdated Aug 21, 2026Diluted EPS (TTM)
-0.6800CNYUpdated Aug 21, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Gross margin is 100%, higher than 95% of its Biotechnology peers (median 67.1%)Significant
Gross margin: 1.00Industry median: 0.67Industry P95: 1.00Peers compared: 261
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 1.00Profit Margin: -2.69
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $5.16M, lower than 95% of all stocks globallySignificant
Revenue (USD): 5,155,415.227Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Gansu Longshenrongfa Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Pharming Group N.V.
Tier 1ProductionApproval-Gated PipelineRule
HK inno.N Corporation
Tier 1ProductionApproval-Gated PipelineRule
R&G Pharmastudies Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Anhui Hongyu Wuzhou Medica Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Beijing Chunlizhengda Medical Instruments Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Genfit S.A.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Chengdu Shengnuo Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Esperion Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Bioventus Inc.
Tier 1ProductionApproval-Gated PipelineRule